Supplementary materials: Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers

These are peer-reviewed supplementary materials for the article 'Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers' published in the Journal of Comparative Effectiveness Research.Supplementary Figure 1: One-way sensitivity analysis for larotrectinib vs. entrectinib on QALYs gained in colorectal cancerSupplementary Figure 2: One-way sensitivity analysis for larotrectinib vs. entrectinib on QALYs gained in soft tissue sarcomaSupplementary Table 1: Sensitivity analysis fitting an exponential curve through the median points for progression-free and overall survival for entrectinibAim: To extrapolate clinical trial results to estimate and compare expected progression-free and overall life years (LYs) and quality-adjusted LYs (QALYs) for larotrectinib and entrectinib in patientswith colorectal cancer (CRC), soft tissue sarcoma (STS) and brain metastases prior to treatment with larotrectinib or entrectinib. Methods: A naive direct comparison of larotrectinib versus entrectinib was made using partitioned survival modeling methods from clinical trial data. Results: Larotrectinib resulted in an additional 1.58 LYs (1.17 QALYs), 5.81 LYs (2.02 QALYs) and 1.01 LYs in CRC, STS and baseline brain metastases, respectively, compared with entrectinib. Conclusion: Larotrectinib provided life expectancy and QALY gains compared with entrectinib. Additional studies will be beneficial as more patients are treated and survival data develop to better inform comparative effectiveness results.